|
A brief news piece dated yesterday...
|
3
|
Resverlogix Corp.
|
Feb 18, 2020 10:09PM
|
|
Barron's rating; albeit a single analyst:
|
3
|
Resverlogix Corp.
|
Dec 06, 2022 01:05PM
|
|
CVD, kidneys, and doctors... oh my!
|
9
|
Resverlogix Corp.
|
Nov 19, 2019 02:28PM
|
|
Epigentic headline:
|
3
|
Resverlogix Corp.
|
May 01, 2024 01:14PM
|
|
Lets go science...
|
6
|
Resverlogix Corp.
|
Nov 02, 2022 12:42PM
|
|
Looking for clues:
|
6
|
Resverlogix Corp.
|
Nov 29, 2019 09:40PM
|
|
Pondering the biomarkers...
|
17
|
Resverlogix Corp.
|
Nov 21, 2019 11:10PM
|
|
Published 8 days ago; review article out of Qatar Univ.
|
6
|
Resverlogix Corp.
|
Feb 14, 2024 01:08PM
|
|
Published today; data on apabetalone in CKD
|
6
|
Resverlogix Corp.
|
Jun 08, 2023 01:01PM
|
|
Re: fish oil and bleeding
|
7
|
Resverlogix Corp.
|
Nov 12, 2019 11:49AM
|
|
Re: 0.05 P-values -- A bridge too far ?
|
7
|
Resverlogix Corp.
|
Feb 13, 2020 10:01PM
|
|
Re: 0.05 P-values -- A bridge too far ?
|
5
|
Resverlogix Corp.
|
Feb 13, 2020 10:24PM
|
|
Re: 0.05 P-values -- A bridge too far ?
|
9
|
Resverlogix Corp.
|
Feb 12, 2020 01:40PM
|
|
Re: AGM
|
3
|
Resverlogix Corp.
|
Jun 06, 2023 10:02PM
|
|
Re: Anybody ever post this link already?
|
3
|
Resverlogix Corp.
|
Apr 14, 2023 12:30PM
|
|
Re: balancing success and failure
|
4
|
Resverlogix Corp.
|
Nov 19, 2019 08:42PM
|
|
Re: Barron's rating; albeit a single analyst:
|
4
|
Resverlogix Corp.
|
Dec 07, 2022 03:59PM
|
|
Re: CRISPR screen identifies COVID19 enabling genes
|
6
|
Resverlogix Corp.
|
Jun 24, 2020 04:41PM
|
|
Re: eGFR and Cognition: Correction:
|
8
|
Resverlogix Corp.
|
Nov 23, 2019 02:47PM
|
|
Re: eGFR and Cognition?
|
6
|
Resverlogix Corp.
|
Nov 22, 2019 10:48PM
|
